VivoScript Inc.

Costa Mesa, CA, United States

VivoScript Inc.

Costa Mesa, CA, United States

Time filter

Source Type

Patent
Vivoscript Inc. | Date: 2017-04-12

A method for repairing cartilage damage comprising (a) creating a microfracture or performing other bone marrow stimulation techniques on a patient inflicted with cartilage damage; and (b) administering a composition to the microfracture, wherein the composition comprises an agent capable of regenerating organized hyaline cartilage.


Patent
Vivoscript Inc. | Date: 2015-06-05

A method for repairing cartilage damage comprising (a) creating a microfracture or performing other bone marrow stimulation techniques on a patient inflicted with cartilage damage; and (b) administering a composition to the microfracture, wherein the composition comprises an agent capable of regenerating organized hyaline cartilage.


Yomogida K.,Oregon Health And Science University | Yomogida K.,Portland Medical Center | Chou Y.,Oregon Health And Science University | Chou Y.,Portland Medical Center | And 7 more authors.
Cytokine | Year: 2012

Streptavidin is widely used as a detection tool in biology research because of its high affinity and specificity binding to biotin. Biotin-streptavidin system has also been explored for detection of infection and tumor in clinical medicine. Here, we show immunosuppressive property of streptavidin on T cell activation and proliferation. Upon CD3 and CD28 stimulation, CD4 + T cells produce interleukin 2 (IL-2) and express IL-2 receptor α chain (CD25). Addition of streptavidin in T cell culture suppressed IL-2 synthesis and CD25 expression with no cytotoxicity. The immunosuppressive effect of streptavidin was reversed by excessive biotin. Conjugated to a single chain anti-CD7 variable fragment (scFvCD7), streptavidin was directly delivered to T cells and showed substantially more profound suppressive effect on T cell activation. These results suggest that streptavidin could potentially be used as a novel immunomodulator. © 2012.


Patent
Oregon Health And Science University and Vivoscript Inc. | Date: 2012-07-19

The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), MSCs, fibroblasts, hematopoietic stem cells, endothelian stem cells, adipocytes, chondrocytes, osteoblasts, osteoclasts and endothelial cells) into chondrogenic cells without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: STTR | Phase: Phase I | Award Amount: 200.08K | Year: 2015

DESCRIPTION provided by applicant The groundbreaking discovery of induced pluripotent stem cells iPSCs has opened a new page for developing personalized cell based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells However the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alteration and tumor formation Generation of iPSCs by transient expression of pluripotent factors has decreased the safety concerns yet the reprogramming efficiency remains low In this application we propose to develop an improved cell permeable protein based method to efficiently generate iPSCs We have developed a rational approach to systematically engineer produce and validate robust cell penetrating reprogramming peptides that will overcome the key barriers to achieve high efficiency and safe cellular reprogramming The technology will enable us to efficiently produce patient compatible iPSCs with the best safety profiles so as to derive other cell types safely for transplantation or for other types of clinical applications Two Aims are proposed Specific Aim Months To construct a library of cell permeable human iPSC reprogramming proteins with modifications that would increase their reprogramming efficiency at Vivoscript Inc Specific Aim Months To evaluate the efficiency of these proteins in iPSC generation in Chenandapos s lab at Sanford Burnham Medical Research Institute PUBLIC HEALTH RELEVANCE We are developing robust cell penetrating peptides to overcome the limitations of current technologies for an efficient generation of human induced pluripotent stem cells iPSCs Our novel technology will enable us to efficiently produce patient compatible iPSCs with the best safety profiles so as to benefit the public by deriving other cell types from these iPSCs for future clinical therapy or drug screens


Patent
Vivoscript Inc. | Date: 2014-07-29

The present inventions are directed to compositions and methods regarding the reprogramming of biological samples (such as cells) without introducing exogenous genes to the sample. In particular, the present inventions are directed to transducible materials that are capable of transducing into the nuclei and have enhanced retention in the nuclei of the biological sample. The present inventions also are directed to methods of reprogramming a biological sample or treating diseases using the transducible compositions thereof.


The present inventions are directed to compositions and methods regarding the reprogramming of biological samples (such as cells) without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the transducible compositions thereof.


The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as glial cells) into neurons without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the transducible compositions thereof.


The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as fibroblast cells) into cardiomyocytes without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.


Patent
Vivoscript Inc. | Date: 2011-11-03

The present disclosure provides a new technology platform that converts one type of cells (substrate cells) to another type of cells (product cells).

Loading VivoScript Inc. collaborators
Loading VivoScript Inc. collaborators